NOWDx develops and manufactures over-the-counter (OTC) and point-of-care (POC) diagnostic tests. Its patented approach enables virtually any immunological assay to be accurately performed onsite in one step using a small amount of capillary blood, yielding results in minutes. With over 75 patents issued and pending, NOWDx's First To Know® and ADEXUSDx® product lines are available in markets worldwide. Founded in 2013, with headquarters and manufacturing in Springdale, Arkansas, NOWDx envisions a world where people have greater access to in-home testing with results in minutes. The company is committed to changing healthcare by providing accessible, affordable, and accurate testing for all.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/10/24 | $22,500,000 | Series B |
DigitalDx Ventures Kompass Kapital Management LabCorp | undisclosed |
